Latest Conference Coverage

Advancing MS Research Through Recognition and Innovation: The John Dystel Prize

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.

Advancing NMOSD Care for Patients: Treatment Access, Education, and Holistic Well-Being

Sumaira Ahmed, founder and executive director of The Sumaira Foundation, discussed how FDA-approved therapies transformed the NMOSD treatment landscape and highlighted ongoing challenges in patient care.

Prioritizing Brain Health in NMOSD Beyond Disease-Modifying Therapies: Sumaira Ahmed

The founder and executive director of the Sumaira Foundation emphasized the critical role of lifestyle factors such as sleep, exercise, and nutrition for maintaining brain health in patients with NMOSD. [WATCH TIME: 3 minutes]

Durability and Next Steps in Advancing ARCUS Gene Editing Platform in DMD: Cassandra Gorsuch, PhD

The chief scientific officer at Precision Biosciences provided clinical insights on the durable potential of ARCUS gene editing and the company’s next steps toward in-human trials for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]

Unveiling ARCUS Gene Editing Platform and Its Potential in DMD: Cassandra Gorsuch, PhD

The chief scientific officer at Precision Biosciences provided clinical commentary on ARCUS gene editing platform and its potential application in Duchenne muscular dystrophy through a durable, AAV-delivered therapeutic strategy. [WATCH TIME: 4 minutes]

Breaking Down Oculopharyngeal Muscular Dystrophy: From Clinical Gaps to Genetic Gains

Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio, offered a clinical and translational overview of OPMD, highlighting current care challenges and the early promise of dual-action gene therapy strategies.

Rethinking Alzheimer Diagnosis and Disease Staging: Clifford Jack, MD

The neuroradiologist at Mayo Clinic discussed the clinical and conceptual differences between Alzheimer disease diagnostic frameworks and how clinicians should prepare for a shifting treatment landscape. [WATCH TIME: 4 minutes]

Exploring a New Oral Option for Alzheimer Treatment With Sonya Miller

Sonya Miller, medical director at TauRx, discussed the latest clinical data and development plans for HMTM, a potential oral therapy targeting tau pathology in Alzheimer disease.

From Fibrosis to Function: Exploring New Pathways in Muscular Dystrophy Research

Neuromuscular expert Matthew Alexander, PhD, explores the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.

Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD

The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]

Preparing for the Future of Rare Disease Treatment: Robert Califf, MD

The former FDA commissioner discussed the collaborative power of the neuromuscular community and the challenges of implementing emerging therapies in a rapidly evolving care landscape. [WATCH TIME: 4 minutes]

Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy

The chief scientific officer at Avidity Biosciences details the mechanism, early results, and future plans for Del-zota, an investigational therapy targeting exon 44 in Duchenne muscular dystrophy.

Celebrating Innovation in MS Research With the John Dystel Prize: Bruce Bebo, PhD

The executive vice president of research at the National MS Society talked about how the award continues to honor transformative multiple sclerosis research and inspire the next generation of investigators. [WATCH TIME: 5 minutes]

Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

A Clinician’s Perspective on First-in-Human Data for LRRK2 Degrader ARV-102

Philip Kremer, MD, Research Director Neurology, Center for Human Drug Research, provided clinical insights on the early-stage progress of ARV-102, an LRRK2 degrader, in LRRK2-associated diseases.

Recognizing and Managing Paraneoplastic Neurological Syndromes: Ditte Primdahl, MD; Shailee Samir Shah, MD

A duo of neurology experts from Feinberg School of Medicine talked about the diagnostic challenges, evolving understanding, and clinical implications of paraneoplastic neurological syndromes. [WATCH TIME: 3 minutes]

Adapting Cognitive Tools for Clinical Trials in Down Syndrome: Elizabeth Head, PhD

The professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, gave clinical insights on efforts to refine neuropsychological outcome measures for individuals with Down syndrome at risk for Alzheimer disease. [WATCH TIME: 3 minutes]

Highlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy: Phil Lambert, PhD

The chief scientific officer at Satellos Bioscience discussed phase 1 findings on SAT-3247, an oral AAK1 inhibitor, highlighting its safety, pharmacokinetics, and early translatability in Duchenne muscular dystrophy. [WATCH TIME: 7 minutes]

Advancements and Challenges in Pediatric Multiple Sclerosis Treatment: Lauren B. Krupp, MD

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study

In a late-stage trial, telitacicept demonstrated significant and rapid clinical improvements in gMG, achieving notable symptom reductions, improved quality of life, and strong safety outcomes.

Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHSc

The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]

Phase 2 RESCUE Data Show RNS60 Reduces Stroke Infarct and Improves Outcomes

High doses of RNS60 led to greater number of patients with modified Rankin scale scores between 0-2, improved EQ-5D-5L index score, and enhanced NIHSS score at each pre-specified time point over placebo.

Safety Profile of CT1812 and Its Effect on Proteomic Biomarkers of Alzheimer Disease: Mary Hamby, PhD

The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]

A New Era in Research: Exploring Cognitive Health and Alzheimer Disease in Down Syndrome

Elizabeth Head, PhD, a professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, shed light on the emerging research and trials surrounding the interplay between Alzheimer disease and Down syndrome.

Felix NeuroAI Wristband Demonstrates Superiority Over Sham Device in TRANQUIL Study for Essential Tremor

In late-breaking findings from the TRANQUIL study presented at AAN 2025, the wearable demonstrated significant improvements in tremor reduction and daily functioning over a sham device.

Improving Timely ALS Diagnosis With the thinkALS Toolkit: Melody Schaeffer, PhD, MPH

The senior director of mission programs at The ALS Association discussed how the thinkALS Toolkit can aid general neurologists in identifying and referring suspected cases more efficiently. [WATCH TIME: 5 minutes]

Real-World Data Reveal Concern of Infections in Efgartigimod for Myasthenia Gravis

Patients treated with efgartigimod for myasthenia gravis were found to have a higher incidence and severity of infections compared to those treated with immunoglobulins.

Building Community and Education Through the AMDAPP CME Conference: Kinsey McCartney, PA-C

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]

Phase 1 Study Supports Further Development of LRRK2 Inhibitor ARV-102

ARV-102 showed dose-dependent LRRK2 degradation and favorable safety in its first-in-human trial, supporting its promise for treating LRRK2-linked neurodegenerative diseases.

Key Insights from ACTRIMS Forum 2025: Diagnostic Criteria, Imaging, and MS Subtypes

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]